CARGO Therapeutics (CRGX) to Release Earnings on Thursday

CARGO Therapeutics (NASDAQ:CRGX) is expected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect CARGO Therapeutics to post earnings of ($0.95) per share for the quarter.

CARGO Therapeutics Price Performance

NASDAQ CRGX opened at $3.80 on Wednesday. The firm’s 50-day moving average is $6.72 and its two-hundred day moving average is $14.35. CARGO Therapeutics has a 12 month low of $3.00 and a 12 month high of $28.13. The stock has a market capitalization of $175.00 million, a P/E ratio of -0.89 and a beta of 1.65.

Analyst Upgrades and Downgrades

A number of research firms have commented on CRGX. JPMorgan Chase & Co. cut shares of CARGO Therapeutics from an “overweight” rating to an “underweight” rating in a research report on Thursday, January 30th. William Blair cut shares of CARGO Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 30th. Truist Financial lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $7.00 in a research note on Thursday, January 30th. Piper Sandler lowered shares of CARGO Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $34.00 to $4.00 in a research note on Thursday, January 30th. Finally, Jefferies Financial Group lowered shares of CARGO Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $3.00 in a research note on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.00.

About CARGO Therapeutics

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.